Ascendis Pharma A/S Return on Equity

Ascendis Pharma A/S (ASND) currently reports a ROE of 52.64%. That is above the Healthcare sector average of 20.77%. Use the charts on this page to explore Ascendis Pharma A/S's ROE history and peer comparisons.

Ascendis Pharma A/S's ROE of 52.64% is higher than the Healthcare sector average of 20.77%. That is roughly 153.5% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Ascendis Pharma A/S's current 52.64% should be judged against Healthcare norms (sector average: 20.77%) and against ASND's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 52.64%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.77%. From there, open related valuation or income-statement pages for Ascendis Pharma A/S, and consider following ASND for alerts when major investors trade the stock.

Ascendis Pharma A/S is classified in the Healthcare sector. On ROE, it currently shows 52.64% versus a sector average near 20.77%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ASND with unrelated industries.